Dermatological adverse events linked to talquetamab immunotherapy in multiple myeloma

BMJ Case Rep. 2024 Nov 26;17(11):e260751. doi: 10.1136/bcr-2024-260751.

Authors

Anas Zayad¹, Maira A Bhatty², Maheen Ahmad³, Faiz Anwer⁴

Affiliations

¹ School of Medicine, The University of Jordan, Amman, Jordan.
² Case Western Reserve University, Cleveland, Ohio, USA.
³ UC Santa Barbara, Santa Barbara, California, USA.
⁴ Hematology Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA [email protected].

PMID: 39603681
DOI: 10.1136/bcr-2024-260751

No abstract available

Keywords: Chemotherapy; Dermatology; Drug interactions; Haematology (drugs and medicines); Malignant and Benign haematology.